DaSH Global retweeted
Our next #Berkshire coffee morning is at 11AM tomorrow! See you there for a coffee and catch up ☕🍩@mesouk #charity #mesothelioma #support #asbestos #HASAG
DaSH Global retweeted
Members of @LASAG_UK & @MerseysideAVS are representing us this week in Liverpool. We are here at The Labour Party Conference 2024 #LabourPartyConference, come & visit our pod where we are discussing current campaigns & issues surrounding asbestos in the UK. #asbestos
DaSH Global retweeted
Volunteer Opportunity: Join Our Medical & Scientific Advisory Panel
ALK+ UK is looking for healthcare professionals or scientists, ideally with an interest in ALK-positive lung cancer, to join our advisory panel.
This is a voluntary role, where your expertise will help shape our work in supporting patients, reviewing publications, and advising on clinical trials.
If you’re a current or retired professional and can offer up to 10 hours a month, we’d love to hear from you.
ALK-positive lung cancer is a relatively rare form of lung cancer that often affects younger people who are non-smokers.
ALK Positive Lung Cancer UK UK is a registered charity that provides support and empowerment to ALK-positive lung cancer patients. We also advocate for best practices throughout the UK and campaign for early diagnosis of non-smoking lung cancer. @rcgp @BTOGORG @LCN_UK @UKlungcancer
DaSH Global retweeted
Establishing consensus-driven pathways places people with #LungCancer at the heart of care. Watch our recent webinar to discover more about how care pathways can be implemented. #LCSM
lungcancerpolicynetwork.com/…
DaSH Global retweeted
Your Health Companion created in response to patients needing a tool to help them manage their condition.
Register as a healthcare professional: health-companion.me/healthca…
#Mesothelioma #LungCancer #Nurses #Clinicians #PatientAdvocacy #PatientOutcomes #NHS #Healthcare #CancerCare
DaSH Global retweeted
The efficacy of almonertinib and anlotinib combination therapy for advanced non-small-cell lung cancer patients who continued to experience cancer progression during third-generation EGFR-TKI treatment: a retrospective study
onlinelibrary.wiley.com/doi/…
DaSH Global retweeted
#LungCancer patients often face challenges when it comes to travel ✈️ yet it can boost wellbeing & QOL. Our new webpage offers tips for managing medication & overcoming other travel hurdles. Plus advice to help make trips safe & enjoyable! egfrpositive.org.uk/travelli… #LCSM #EGFR
DaSH Global retweeted
FRIDAY NEWS: VOICES OF LuCE
Our #FridayNews this week comes from the UK where our members @UKALK1 & @LCN_UK presented a research poster at the Lung Cancer Nursing UK Annual Conference in Glasgow.
1/2
DaSH Global retweeted
Lovely to see so many happy people at our Southampton coffee morning today, such a friendly supportive group, looking forward to next month already Mesothelioma UK #charity #support #mesothelioma
DaSH Global retweeted
LCNUK would like to thank Professor Alison Leary, who is stepping down as a trustee of the charity, for her commitment to the role.
We are grateful to Alison for her guidance and support of LCNUK over the years.
Thank you!
DaSH Global retweeted
Inclusion of quality-of-life metrics and patient-reported outcomes in lung cancer clinical trials is disappointingly and unacceptably low, as highlighted by Dr @pompili_cecilia at #ELIXR24.
DaSH Global retweeted
Using @Health_Compan to collect health data is easy, convenient & secure: Providing accurate, personalised insights to support self-management, improve communication with your health team and opportunities for research. Download for free today: health-companion.me
DaSH Global retweeted
Integrating Patient Reported Outcomes data into drug evaluation process can enhance understanding of a #cancer drug's benefits and risks, and ultimately accelerate access to new cancer drugs. By downloading Your Health Companion & recording your feedback - you can #drivechange
DaSH Global retweeted
Data obtained from Patient Reported Outcomes Measures #PROMs and Patient Reported Experience Measures #PREMs collected via @Health_Compan delivers quantified, measured feedback invaluable for providing insights into the effectiveness, appropriateness & acceptability of therapies.
DaSH Global retweeted
We're contesting #Mobocertinib's withdrawal in March - it's the only UK licensed TKI for #EGFR+ Exon 20 patients. Our case will be debated in @UKHouseofLords 14 Feb. New/existing patients can access until Mar. Existing via the @TakedaOncology compassionate use programme after.

ALT A graphic with an image of a lung X-ray indicating lung cancer, and a Mobocertinib medication bottle on the right. Overlaid text reads 'Mobocertinib: A Lifeline at Risk' and 'The sole TKI licensed in the UK for EGFR+ Exon 20 patients faces withdrawal this March.' The EGFR+ UK logo is at the bottom.
DaSH Global retweeted
Research will help @mesouk develop priorities and shape services going forward - directly benefiting people affected by #mesothelioma.
#MakeYourExperienceCount mesothelioma.uk.com/experien…
Sign up for Your Health Companion.
health-companion.me/news-upd…
DaSH Global retweeted
A recent survey of health teams using @Health_Compan in clinics - ALL respondents reported real benefits to them and their service of patients using Your Health Companion. 92% reporting it helps patients better manage their condition.
Find out more health-companion.me
DaSH Global retweeted
We're delighted to partner with @EgfrUk to support patients living with EGFR positive lung cancer to help manage their condition and drive research into non-smoking lung cancer. Download @Health_Compan today health-companion.me
#BeInformed #SupportResearch #DriveChange
DaSH Global retweeted
We collect Patient Reported Outcomes securely, continuously and accurately from patients nationally. Anonymised PROMS data helps drive #research into new treatments to improve the lives of those living with, and beyond, cancer.
Add your voice. Sign up. health-companion.me
DaSH Global retweeted
The @Health_Compan app has the potential to transform our conversations with patients with #LungCancer and improve the care we can deliver.
If you are not yet participating in this programme, please consider getting involved in this important venture ➡️ ow.ly/9T2T50MhbF7




























